Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds

NARecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions
Nasolabial Folds
Interventions
DEVICE

Ellanse S

Ellanse S polycaprolactone and carboxymethylcelluose gel based dermal filler syringe

DEVICE

Calcium Hydroxylapatite-based filler

Calcium Hydroxylapatite and carboxymethylcellulose based filler

Trial Locations (7)

20769

NOT_YET_RECRUITING

Callender Center for Clinical Research, Glenn Dale

33146

RECRUITING

Skin Research Institute LLC, Miami

48088

NOT_YET_RECRUITING

Advanced Dermatology of Michigan, Warren

86260

NOT_YET_RECRUITING

Investigate MD, Scottsdale

91436

NOT_YET_RECRUITING

Clinical Testing of Beverly Hills, Encino

06880

NOT_YET_RECRUITING

DMR Research, PLLC, Westport

02467

NOT_YET_RECRUITING

Skincare Physicians, Chestnut Hill

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Sinclair Pharmaceuticals Limited

INDUSTRY

lead

AQTIS Medical B.V.

OTHER

NCT06984835 - Safety and Effectiveness of ELLANSÉ®-S Dermal Filler in the Treatment of Nasolabial Folds | Biotech Hunter | Biotech Hunter